SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Overlooked infertility care should be part of national health services, says WHO - 2Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid.
- 375% of US adults may meet criteria for obesity under new definition, study finds
- 4Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- 5Are protests pushing Iran's Islamic regime toward a tipping point?
- An eye for an eye: People agree about the values of body parts across cultures and eras
- Dark matter obeys gravity after all — could that rule out a 5th fundamental force in the universe?
- Inconceivable Spots To Stargaze All over The Planet
- Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- Really focusing on Succulents: Tips and Procedures
- A top Marine shares his secrets to keeping fit at 50
- Recalled "super greens" supplement linked to dozens of salmonella cases, CDC says
- More loons are filling Maine's lakes with their ghostlike calls
- What to know as New York City nurses strike for a 3rd day
